一种小分子PKCε抑制剂可以减少由帕克利塔塞尔或阿片类药物戒断引起的过敏症
Adriana Gregory-Flores1,2, Ivan Jm Bonet3,4, Stève Desaivre2
1Institute for Neuroscience and.
JCI insight
|April 22, 2025
概括
一种新的药物CP612,向蛋白质激酶Cepsilon (PKCε),有效治疗化疗疼痛和阿片类药物戒断症状. 这种非成的方法为患有阿片类药物依赖症的慢性疼痛患者提供了希望.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
- 疼痛管理 疼痛管理
背景情况:
- 蛋白质激酶Cepsilon (PKCε) 与疼痛信号通路有关.
- 慢性疼痛,特别是化疗引起的神经病痛,往往没有得到充分的治疗.
- 随着时间的推移,阿片类药物可能会失去有效性,导致依赖,戒断会加剧疼痛.
研究的目的:
- 评估一种新型PKCε抑制剂CP612在动物化疗诱导的神经病痛模型中的疗效.
- 为了确定CP612是否可以预防或逆转与阿片类药物戒断相关的疼痛.
- 评估CP612的滥用潜力.
主要方法:
- 开发和管理小分子PKCε抑制剂,CP612.
- 使用帕克利塔塞尔诱导的动物模型治疗化疗诱导的神经病痛.
- 研究了CP612对阿片类药物戒断诱导的过敏症和药物自我管理的影响.
主要成果:
- CP612显著减弱了帕克利塔塞尔诱导的过敏症.
- CP612显示了对阿片类药物戒断引起的过敏症的预防和逆转作用.
- CP612没有表现出自我给药的迹象,也没有影响吗啡的自我给药.
结论:
- 用CP612抑制PKCε是一种可行的,非成的治疗策略,用于化疗诱导的神经病痛.
- 在停用阿片类药物期间,CP612在治疗疼痛方面具有潜在的好处,有助于慢性疼痛和阿片类药物依赖的患者.
相关概念视频
Analgesia and Pain Management
397
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
397
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
134
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
134
GPCR Desensitization
5.6K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.6K
Desensitization and Tachyphylaxis
1.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.4K
Nociception
27.6K
Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
27.6K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
171
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
171


